New research reveals that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Published data in a leading health publication demonstrates that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using these treatments must be aware of the danger of quick weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight within about a year and a half.
Weighing Approaches
The analysis, which examined dozens of studies involving thousands of patients, contrasted the results of these new drugs with older methods.
The team point out that people who shed pounds through diet and exercise typically experience a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Nutrition scientists suggest the way of the injections accounts for the heightened regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls hunger.
"Artificially providing GLP-1 levels far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
The NHS recommend the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of relapse, the treatment might need to be ongoing.
This opinion is reinforced by drug manufacturers, who state that the results "emphasize the chronic character of obesity," akin to managing diseases like high blood pressure.
User Accounts
Individuals who have stopped the medication describe a powerful resurgence of cravings.
"It was like a trigger that goes on and I was suddenly starving," said one woman.
The struggle is worsened if users have not adopted lasting lifestyle or habit modifications during therapy.
Widespread Interest
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is greater among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
Finally, researchers emphasize that while the jabs are potent tools for weight loss, they are not a permanent cure and long-term success likely depends on combined behavioural changes.
